Kancera's patent covering small molecule inhibitors of PFKFB3 has been approved in the United States. Further, a patent application covering new chemical series in the HDAC6 project has been filed according to plan. In the ROR project, the company...
Read MoreKancera hereby provides an operational update on the PFKFB3 and HDAC6 projects as well as the EU-funded epigenetically targeted parasitic project A-PARADDISE.
Read MoreIn connection with a meeting arranged by the Swedish Shareholders' Association in Malmö on September 30, Kancera provides an operational update on the ROR and Fractalkine projects.
Read MoreKancera has entered into an agreement with Acturum Life Science AB in order to evaluate and further develop the unique Fractalkine inhibitor AZD8797. Published research points to that Fractalkine signaling probably contributes to the growth and spread of tumors...
Read MoreKancera reports results from the company's cancer project portfolio generated in 2015.
Read MoreKancera reports that a second efficacy study of the drug candidate KAN0439834 (small molecule inhibitor of ROR1) has been completed in an animal model of an advanced stage of chronic lymphocytic leukemia. The results show that KAN0439834 reduces the...
Read MoreKancera reports that an investigation of the mechanism of action of the company's patent-pending HDAC6 inhibitors has demonstrated a unique profile that could strengthen the competitiveness of the project.
Read MoreKancera reports the results of an analysis of the preclinical efficacy study that was completed during the third quarter as reported in a press release on October 3, 2014. The results confirm that the number of cancer cells in...
Read MoreKancera reports that an initial efficacy study of KAN0439834 (a small molecule inhibitor of ROR1) has been completed in an animal model of chronic lymphocytic leukemia. Preliminary results show that KAN0439834 reduces the number of ROR-expressing leukemia cells after...
Read MoreIn connection with presentations for pharmaceutical companies and universities during the "U.S. Cancer Immunotherapy Partnering Mission" (CIPM), 15 -19 September 2014, Kancera communicates new information regarding the company's ROR1-directed small molecules and vaccine candidates. This information concerns the efficacy...
Read More